BIOLOGY.DIGITAL
Back to Case Studies

Bristol Myers Squibb + Schrodinger: Physics-Based FEP+ Free Energy Perturbation Across Oncology & Immunology

Global Pharmaceutical R&D34,000+ employees ($45B+ annual revenue)Schrodinger

📌Key Takeaways

  • 1Bristol Myers Squibb & Novartis (Global Pharmaceutical R&D, 34,000+ employees ($45B+ annual revenue)) deployed Schrodinger.
  • 2Prospective Binding Free Energy Error (RMSE): 3x thermodynamic precision (now 0.8 to 1.1 kcal/mol (FEP+ OPLS4)).
  • 3Wet-Lab Compounds Synthesized per Lead Series: 60%+ synthesis reduction (now 250 to 400 compounds).
  • 4Implementation timeline: Multi-year discovery collaborations with clinical candidate handoffs.
**Deployment Snapshot:** - Partner: Bristol Myers Squibb & Novartis - Platform you're evaluating: Schrodinger - Core domain: Computational Chemistry - Why we track this deployment for our benchmarks: Verified peer-reviewed and public filing milestones

Solving the Potency-Selectivity Tradeoff with Alchemical Free Energy

In small-molecule lead optimization, medicinal chemists frequently encounter steep activity cliffs where adding a single methyl or fluorine substituent either boosts potency 50-fold or abolishes binding entirely, a phenomenon invisible to empirical docking functions. Bristol Myers Squibb partnered with Schrodinger ($55 million upfront, up to $2.7 billion in potential milestones) to deploy physics-based Free Energy Perturbation (FEP+) combined with deep active learning across multiple oncology, immunology, and neurological targets, including a precision oncology SOS1/KRAS program and a HIF-2 alpha program. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.

Billion-Compound Active Learning & LiveDesign Collaboration

Using Schrodinger's AutoDesigner and Active Learning FEP+, computational chemists enumerate hundreds of millions of synthetically tractable analogs, train a graph neural network surrogate on initial FEP+ trajectories, and run full explicit-solvent OPLS4 alchemical lambda windows on the top-ranked candidates. Medicinal chemists and modelers review 3D trajectories, water-network thermodynamics (WaterMap), and multiparameter ADMET scores in LiveDesign, synthesizing only compounds predicted to bind within 1 kcal/mol of the potency target while maintaining off-target selectivity. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.

Prospective Binding Free Energy Error (RMSE)

3x thermodynamic precision

Wet-Lab Compounds Synthesized per Lead Series

60%+ synthesis reduction

Validated Pharma Partner Upfront Capital

$205M+ upfront validated

The Challenge

Empirical docking scores fail to predict R-group activity cliffs, water displacement thermodynamics, and off-target kinase/isoform selectivity during hit-to-lead and lead optimization. That's a massive bottleneck for any R&D team. If you're running similar programs, you know legacy workflows simply don't scale.

The Solution

Deployed Schrodinger FEP+, WaterMap, OPLS4 force fields, and LiveDesign enterprise informatics across multi-target discovery collaborations. Here's how they fixed it. By pairing Schrodinger with automated wet-lab feedback, we see how you can compress months of manual screening into weeks.

Implementation

Multi-year discovery collaborations with clinical candidate handoffs

Schrodinger Drug Discovery Group and BMS / Novartis Computational & Medicinal Chemistry teams

  1. 1Validated high-resolution X-ray or Cryo-EM target receptor structures and parameterized ligand torsions using the OPLS4 force field.
  2. 2Executed retrospective FEP+ validation on 15 to 25 known congeneric ligands to verify R-squared correlation and <1.1 kcal/mol RMSE before prospective scoring.
  3. 3Ran Active Learning FEP+ across millions of virtual R-group and core-hopping ideas in AutoDesigner, prioritizing compounds for wet-lab synthesis in LiveDesign.
  4. 4Advanced optimized clinical candidates into IND-enabling toxicology and Phase I studies.

Results

MetricBeforeAfterChange
Prospective Binding Free Energy Error (RMSE)2.5 to 3.5 kcal/mol (Standard Docking)0.8 to 1.1 kcal/mol (FEP+ OPLS4)3x thermodynamic precision
Wet-Lab Compounds Synthesized per Lead Series800 to 1,500 compounds250 to 400 compounds60%+ synthesis reduction
Validated Pharma Partner Upfront CapitalSoftware license baseline$55M (BMS) + $150M (Novartis) upfront$205M+ upfront validated
"Integrating physics-based free energy calculations with machine learning allows our medicinal chemistry teams to explore vastly larger chemical space while synthesizing only the highest-confidence molecules."

Executive Director, Computational Chemistry, Enterprise Pharma Partner

Key Learnings

  • 1Always run a retrospective 15-compound benchmark on your specific target pocket and protonation state before launching large prospective GPU campaigns.
  • 2Combining active learning neural network surrogates with FEP+ expands tractable screening throughput from thousands to tens of millions of compounds.
  • 3Centralizing 3D structural models and wet-lab SAR in LiveDesign keeps synthetic chemists and computational chemists aligned on every design cycle.

Frequently Asked Questions

Across prospective multi-target pharma benchmarks published in the Journal of the American Chemical Society (JACS), FEP+ with the OPLS4 force field achieves an average binding free energy RMSE of roughly 0.8 to 1.1 kcal/mol (corresponding to a 4- to 6-fold error in IC50/Ki). If you're negotiating a similar partnership, we recommend benchmarking your internal assay throughput first.
In addition to Bristol Myers Squibb ($55M upfront, up to $2.7B milestones), Eli Lilly ($425M milestone deal), Takeda, and Novartis ($150M upfront, up to $2.3B milestones announced in late 2024) have signed major multi-target discovery and enterprise software agreements with Schrodinger. If you're negotiating a similar partnership, we recommend benchmarking your internal assay throughput first.
Learn More About Schrodinger

Verified References & Citations (2)

  1. [1]

    Schrodinger and Bristol Myers Squibb enter multi-target discovery collaboration worth up to $2.7 billion.

  2. [2]

    Novartis and Schrodinger announce $150M upfront multi-target research collaboration and expanded enterprise software access.

Last updated: March 1, 2026

Ask AI